LogicBio Therapeutics Inc

-0.01 (-0.22%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)107.31M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$10.45 Million
Adjusted EPS-$0.13
See more estimates
10-Day MA$4.92
50-Day MA$6.58
200-Day MA$7.16
See more pivots

LogicBio Therapeutics Inc Stock, NASDAQ:LOGC

65 Hayden Avenue, 2nd floor, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.245.0399
Number of Employees: 39


LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline include LB-001, LB-301, LB-201, and LB-101. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.